Taken together, our data identified CUX1 as an important enhancer of KRAS-induced tumor development in pancreatic cancer, acting synergistically with oncogenic KRAS by inducing several upstream and downstream effectors such as ADAM17 and MOS. Here, KRAS is linked to familial pancreatic carcinoma.